1. Home
  2. JTAI vs REVB Comparison

JTAI vs REVB Comparison

Compare JTAI & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jet.AI Inc.

JTAI

Jet.AI Inc.

HOLD

Current Price

$9.04

Market Cap

4.6M

Sector

Finance

ML Signal

HOLD

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

HOLD

Current Price

$1.07

Market Cap

4.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JTAI
REVB
Founded
2018
2020
Country
United States
United States
Employees
8
9
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6M
4.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
JTAI
REVB
Price
$9.04
$1.07
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$80.00
N/A
AVG Volume (30 Days)
161.8K
56.1K
Earning Date
05-15-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.73
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.04
$0.47
52 Week High
$10.41
$3.21

Technical Indicators

Market Signals
Indicator
JTAI
REVB
Relative Strength Index (RSI) 66.84 48.96
Support Level $6.03 $1.06
Resistance Level $9.24 $1.20
Average True Range (ATR) 0.69 0.05
MACD 0.10 0.01
Stochastic Oscillator 88.29 78.87

Price Performance

Historical Comparison
JTAI
REVB

About JTAI Jet.AI Inc.

Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as through Jet Token's leased and managed aircraft.

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.

Share on Social Networks: